SCHEMBL3325855

SCHEMBL3325855

Cc1ccc(OC[C@H]2CCCNC2)c(Oc2ccc(Cl)cc2Cl)n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 5/20 0.45
SLC6A4 P31645 2/20 0.44
HTR1A P08908 1/20 0.44
SLC6A2 P23975 1/20 0.44
HTR6 P50406 1/20 0.44
MAP2K1 Q02750 2/20 0.42
IKBKB O14920 1/20 0.42
CHUK O15111 1/20 0.42
KCNH2 Q12809 1/20 0.41
KCNJ6 P48051 1/20 0.40
KCNJ3 P48549 1/20 0.40
IRAK4 Q9NWZ3 3/20 0.40
PIM1 P11309 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
CTSS P25774 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3325306 1.00 S1PR4 (0.45) S1PR4SLC6A4HTR1ASLC6A2HTR6
SCHEMBL3324733 0.93 MAP2K1 (0.43) SLC6A4HTR6MAP2K1IKBKBCHUK
SCHEMBL3328810 0.93 MAP2K1 (0.43) SLC6A4HTR6MAP2K1IKBKBCHUK
SCHEMBL3324210 0.90 SCN9A (0.44) S1PR4SLC6A4SLC6A2HTR6MAP2K1
SCHEMBL3325149 0.90 MAP2K1 (0.41) S1PR4SLC6A4HTR1ASLC6A2MAP2K1
SCHEMBL3320864 0.90 SCN9A (0.44) S1PR4SLC6A4SLC6A2HTR6MAP2K1
SCHEMBL3324992 0.90 SLC6A4 (0.45) S1PR4SLC6A4SLC6A2HTR6IKBKB
SCHEMBL3324999 0.90 SLC6A4 (0.45) S1PR4SLC6A4SLC6A2HTR6IKBKB
SCHEMBL3325140 0.90 MAP2K1 (0.41) S1PR4SLC6A4HTR1ASLC6A2MAP2K1
SCHEMBL3324465 0.89 EED (0.43) S1PR4SLC6A4SLC6A2MAP2K1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US claimed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP claimed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO claimed
US-20100120858-A1 Piperidine Derivatives PFIZER INC. 2010-05-13 US disclosed
EP-2066630-A1 PIPERIDINE DERIVATIVES Pfizer Products Incorporated (US) 2009-06-10 EP disclosed
WO-2008023258-A1 PIPERIDINE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120858-A1 Piperidine Derivatives P2RX5, P2RX7, P2RX1 S1PR4 160/4885SLC6A4 1898/4885HTR1A 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.